Vaxdyn

Vaxdyn is a Spanish biotechnology company focused on developing vaccines to combat the global crisis of antimicrobial resistance (AMR). The company specializes in creating multivalent vaccines that target World Health Organization (WHO) priority Gram-negative pathogens, including Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Their lead candidate, VAXDYN-001, is designed to provide broad-spectrum protection for vulnerable populations such as patients with chronic obstructive pulmonary disease (COPD) or those undergoing surgery. Supported by significant non-dilutive funding from CARB-X, Vaxdyn utilizes a proprietary platform to produce vaccines that trigger robust immune responses against conserved bacterial antigens. The company's mission is to reduce global dependency on antibiotics and prevent life-threatening hospital-acquired infections.